• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定一名患有磷酸肌醇 3-激酶 δ 综合征的患者中 PIK3CD 的新型从头获得性功能突变。

Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.

机构信息

Department of Immunology, Shenzhen Children's Hospital, Shenzhen, China.

BGI-Shenzhen, Shenzhen, China.; China National GeneBank, BGI-Shenzhen, Shenzhen, China.

出版信息

Clin Immunol. 2018 Dec;197:60-67. doi: 10.1016/j.clim.2018.08.007. Epub 2018 Aug 20.

DOI:10.1016/j.clim.2018.08.007
PMID:30138677
Abstract

Activated phosphoinositide 3-kinase δ (PI3Kδ) syndrome is a newly defined and relatively common primary immunodeficiency, which is caused by heterozygous gain-of-function (GOF) mutations in PIK3CD or PIK3R1. Here, we report a novel de novo GOF mutation (c.1570 T > A, p.Y524N) in PIK3CD in a 6-year-old Chinese girl. The patient suffered recurrent sinopulmonary infection, bronchiectasis, lymphoproliferation, herpesvirus infection, and distinctive nodular lymphoid hyperplasia of mucosal surfaces. Immunological analysis revealed increased CD4+ T cell senescence and B cell immaturity. Further analysis revealed an increase in almost all CD4+ T cell subsets to varying degrees, including effector T cells and Treg cells. Increased levels of plasma T cell-related cytokines corroborated these results. Hyperactivation of the PI3Kδ-Akt-mTOR signaling pathway was also confirmed. Treatment with rapamycin ameliorated the lymphoproliferative immunodeficiency caused by hyperactivation of mTOR. These results expand genetic spectrum of APDS and will facilitate further study of the genotype-phenotype correlation in those with PIK3CD mutations.

摘要

活化的磷酯酰肌醇 3-激酶 δ(PI3Kδ)综合征是一种新定义的且相对常见的原发性免疫缺陷病,其由 PIK3CD 或 PIK3R1 的杂合获得性功能(GOF)突变引起。在此,我们报告了一例 6 岁中国女孩中 PIK3CD 中的新型从头 GOF 突变(c.1570T>A,p.Y524N)。该患者反复发生肺鼻窦感染、支气管扩张、淋巴组织增生、疱疹病毒感染以及黏膜表面特有的结节状淋巴组织增生。免疫学分析显示 CD4+T 细胞衰老和 B 细胞不成熟增加。进一步分析显示,几乎所有 CD4+T 细胞亚群都不同程度地增加,包括效应 T 细胞和 Treg 细胞。血浆 T 细胞相关细胞因子水平升高证实了这些结果。PI3Kδ-Akt-mTOR 信号通路的过度激活也得到了证实。雷帕霉素治疗改善了由 mTOR 过度激活引起的淋巴组织增生性免疫缺陷。这些结果扩展了 APDS 的遗传谱,并将有助于进一步研究 PIK3CD 突变患者的基因型-表型相关性。

相似文献

1
Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.鉴定一名患有磷酸肌醇 3-激酶 δ 综合征的患者中 PIK3CD 的新型从头获得性功能突变。
Clin Immunol. 2018 Dec;197:60-67. doi: 10.1016/j.clim.2018.08.007. Epub 2018 Aug 20.
2
Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome.活化磷酸肌醇 3-激酶 δ 综合征的中国队列报告。
J Clin Immunol. 2018 Nov;38(8):854-863. doi: 10.1007/s10875-018-0568-x. Epub 2018 Nov 29.
3
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.活化磷脂酰肌醇3-激酶δ综合征的临床谱和特征:一项大型患者队列研究。
J Allergy Clin Immunol. 2017 Feb;139(2):597-606.e4. doi: 10.1016/j.jaci.2016.06.021. Epub 2016 Jul 16.
4
Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.激活 PIK3CD 突变会损害人类细胞毒性淋巴细胞的分化和功能,并影响 EBV 免疫。
J Allergy Clin Immunol. 2019 Jan;143(1):276-291.e6. doi: 10.1016/j.jaci.2018.04.030. Epub 2018 May 22.
5
Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.活化的磷酯酰肌醇 3-激酶 δ 综合征的呼吸表现。
Front Immunol. 2018 Mar 5;9:338. doi: 10.3389/fimmu.2018.00338. eCollection 2018.
6
Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8 T Cell Survival, Differentiation, and Function.磷酸肌醇 3-激酶 δ 的遗传缺陷影响 CD8 T 细胞的存活、分化和功能。
Front Immunol. 2018 Aug 2;9:1758. doi: 10.3389/fimmu.2018.01758. eCollection 2018.
7
[Clinical and immunological analysis of patients with activated phosphoinositide 3-kinase δ syndrome resulting from PIK3CD mutation].[PIK3CD 突变导致的活化磷脂酰肌醇 3 - 激酶δ综合征患者的临床和免疫学分析]
Zhonghua Er Ke Za Zhi. 2017 Jan 2;55(1):19-24. doi: 10.3760/cma.j.issn.0578-1310.2017.01.004.
8
Early diagnosis of PI3Kδ syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.2 岁女童反复中耳炎伴脾大,提示早发型 PI3Kδ 综合征
Immunol Lett. 2017 Oct;190:279-281. doi: 10.1016/j.imlet.2017.08.021. Epub 2017 Aug 31.
9
Exhaustion of the CD8 T Cell Compartment in Patients with Mutations in Phosphoinositide 3-Kinase Delta.磷酸肌醇 3-激酶 δ 突变患者的 CD8 T 细胞区室耗竭。
Front Immunol. 2018 Mar 7;9:446. doi: 10.3389/fimmu.2018.00446. eCollection 2018.
10
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.激活的磷酸肌醇 3-激酶 δ 综合征 2 相关的临床和免疫表型:一项队列研究。
J Allergy Clin Immunol. 2016 Jul;138(1):210-218.e9. doi: 10.1016/j.jaci.2016.03.022. Epub 2016 Apr 21.

引用本文的文献

1
Systematic literature reviews to identify epidemiological, clinical, economic and health-related quality of life evidence in activated PI3Kδ syndrome (APDS).系统性文献综述,以识别活化磷脂酰肌醇-3-激酶δ综合征(APDS)的流行病学、临床、经济和健康相关生活质量证据。
BMC Immunol. 2025 Jul 19;26(1):52. doi: 10.1186/s12865-025-00723-6.
2
Overall survival among patients with activated phosphoinositide 3-kinase delta syndrome (APDS).活化磷脂酰肌醇3-激酶δ综合征(APDS)患者的总生存期。
Orphanet J Rare Dis. 2025 May 3;20(1):212. doi: 10.1186/s13023-025-03734-z.
3
Genetic Etiologies and Outcomes in Malignancy and Mortality in Activated Phosphoinositide 3-Kinase Delta Syndrome: A Systematic Review.
活化磷脂酰肌醇3-激酶δ综合征的遗传病因与恶性肿瘤及死亡率的结局:一项系统综述
Adv Ther. 2025 Feb;42(2):752-771. doi: 10.1007/s12325-024-03066-7. Epub 2024 Dec 5.
4
Genetic Testing in Patients with Autoimmune Lymphoproliferative Syndrome: Experience of 802 Patients at Cincinnati Children's Hospital Medical Center.自身免疫性淋巴组织增生综合征患者的基因检测:辛辛那提儿童医院医疗中心 802 例患者的经验。
J Clin Immunol. 2024 Jul 26;44(7):166. doi: 10.1007/s10875-024-01772-z.
5
Activated phosphoinositide 3-kinase δ syndrome caused by PIK3CD mutations: expanding the phenotype.PIK3CD 突变导致的活化磷酯酰肌醇 3-激酶 δ 综合征:扩展表型。
Pediatr Rheumatol Online J. 2024 Jan 29;22(1):24. doi: 10.1186/s12969-024-00955-7.
6
Systematic review of mortality and survival rates for APDS.APDS 死亡率和生存率的系统评价。
Clin Exp Med. 2024 Jan 27;24(1):17. doi: 10.1007/s10238-023-01259-y.
7
Treg in inborn errors of immunity: gaps, knowns and future perspectives.固有免疫缺陷中的调节性 T 细胞:差距、已知和未来展望。
Front Immunol. 2024 Jan 8;14:1278759. doi: 10.3389/fimmu.2023.1278759. eCollection 2023.
8
Rescuing the cytolytic function of APDS1 patient T cells via TALEN-mediated PIK3CD gene correction.通过TALEN介导的PIK3CD基因校正挽救APDS1患者T细胞的细胞溶解功能。
Mol Ther Methods Clin Dev. 2023 Oct 10;31:101133. doi: 10.1016/j.omtm.2023.101133. eCollection 2023 Dec 14.
9
Activated PI3Kδ syndrome - reviewing challenges in diagnosis and treatment.活化的 PI3Kδ 综合征 - 诊断和治疗中的挑战综述。
Front Immunol. 2023 Jul 20;14:1208567. doi: 10.3389/fimmu.2023.1208567. eCollection 2023.
10
The Cross Talk between Cellular Senescence and Melanoma: From Molecular Pathogenesis to Target Therapies.细胞衰老与黑色素瘤之间的相互作用:从分子发病机制到靶向治疗
Cancers (Basel). 2023 May 6;15(9):2640. doi: 10.3390/cancers15092640.